Drug
PA21 clinical trials
Also written PA21.
- studies test it
- 10
- open now
- 0
- in phase 3
- 7
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
- PA21
- 8
Studies by the year they started
9 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 3 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 1
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Kissei Pharmaceutical Co., Ltd. (5) · Vifor Pharma (4) · Vifor Fresenius Medical Care Renal Pharma (1)
Studies
Open first, then newest update. How each study uses PA21 is read from its arms, and is right about nine times in ten.
Testing it · 10
- PA21 Safety and Efficacy in Adult Chinese SubjectsCompletedPhase 3Vifor Fresenius Medical Care Renal PharmaNCT03644264Written as PA21
- A Long-term Study of PA21 in Hemodialysis Patients With HyperphosphatemiaCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01833494Written as PA21
- A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With HyperphosphatemiaCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01850641Written as PA21
- A Phase III Study of PA21 in Hemodialysis Patients With HyperphosphatemiaCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01850602Written as PA21
- PA21 Phase II Clinical Study in Hemodialysis Patients With HyperphosphatemiaCompletedPhase 2Kissei Pharmaceutical Co., Ltd.NCT01521494Written as PA21
- A Phase III Study of PA21 in Peritoneal Dialysis Patients With HyperphosphatemiaCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01852682Written as PA21
- A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis PatientsCompletedPhase 3Vifor PharmaNCT01324128Written as PA21 (2.5 g tablet containing 500 mg iron)
- A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis PatientsCompletedPhase 3Vifor PharmaNCT01464190Written as PA21 (2.5 g tablet containing 500 mg iron)
- A Drug-Drug Interaction Study of Warfarin and PA21CompletedPhase 1Vifor PharmaNCT01477424Written as PA21
- A Drug-Drug Interaction Study of Digoxin and PA21CompletedPhase 1Vifor PharmaNCT01477411Written as PA21